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 Abstract 
 Coagulation factor XIII (FXIII) is converted by thrombin 
and Ca 2 +  into an active transglutaminase (FXIIIa) in the 
fi nal phase of coagulation cascade. Its main function is 
the mechanical stabilization of fi brin clot and its protec-
tion from fi brinolysis by cross-linking of fi brin chains and 
 α 2 -plasmin inhibitor to fi brin. In non-substituted patients 
FXIII defi ciency is a severe hemorrhagic diathesis, not 
infrequently with fatal consequences. The main reason for 
using FXIII assays is the diagnosis of FXIII defi ciency. The 
aim of this review is to provide a comprehensive critical 
evaluation of the methods reported for the determination of 
FXIII activity in the plasma. Such methods are based on two 
principles: 1) measurement of labeled amines incorporated 
by FXIIIa into a glutamine residue of a substrate protein, 
2) monitoring ammonia released from a peptide bound glu-
tamine residue by FXIIIa using NAD(P)H dependent glu-
tamate dehydrogenase indicator reaction. The incorporation 
assays are sensitive, but cumbersome and time-consuming, 
they are diffi cult to standardize and cannot be automated. 
The ammonia release assays are less sensitive, but quick, 
well standardized, and can be automated; this type of assay 
is recommended for the screening of FXIII defi ciency. The 
traditional clot solubility assay should not be used for this 
purpose. 
 Keywords:  factor XIII;  factor XIII assays;  factor XIII 
defi ciency . 
 Introduction 
 Coagulation factor XIII (FXIII) is a zymogen of tetra-
meric structure (FXIII-A 2 B 2 ) that consists of two catalytic 
A subunits (FXIII-A) and two carrier/inhibitory B subunits 
(FXIII-B). FXIII-A is synthesized by cells of bone marrow 
origin, while FXIII-B is produced by hepatocytes. The two 
subunits form complex in the plasma. FXIII-B is in excess 
and approximately 50 % of it exists in free non-complexed 
form. FXIII circulates in association with fi brinogen. FXIII 
is also present in platelets and monocytes/macrophages, 
however this cellular form is a dimer of FXIII-A (FXIII-A 2 ), 
which lacks FXIII-B. In plasma FXIII is activated by the con-
certed action of thrombin and Ca 2 +  , fi rst thrombin cleaves off 
the activation peptide of 37 amino acids from the N-terminal 
end of FXIII-A, then in the presence of Ca 2 +  FXIII-A and 
FXIII-B dissociate and the cleaved FXIII-A 2 assumes an 
enzymatically active confi guration. The presence of polym-
erized fi brin highly (80 to 100-fold) accelerates the activa-
tion process, and, if fi brin is present, the activation occurs 
on the surface of fi brin polymers. In cells, in the absence 
of FXIII-B, the elevation of Ca 2 +  concentration is suffi cient 
to bring about the active confi guration. For more informa-
tion on the structure and function of FXIII interested readers 
should consult most recent extensive reviews  (1, 2) . 
 Activated FXIII (FXIIIa) is a transglutaminase (protein-
glutamine: amine  γ -glutamyltransferase, EC 2.3.2.13) that 
catalyzes an acyl transfer reaction, in which the carboxam-
ide group of a peptide/protein-bound glutamine residue is 
the acyl donor and an appropriate primary amine substrate 
is the acyl acceptor  (3, 4) . Figure  1 demonstrates a simpli-
fi ed scheme of the transglutaminase reaction. The reaction 
proceeds through an oxyanion intermediate (not shown on 
the Figure), and ammonia is released as the acyl-enzyme 
intermediate, a thioesther between the peptide bound glu-
tamine and the -SH group of the active-site cysteine of 
FXIIIa, is formed. Then, in the presence of a substrate pri-
mary amine, the acyl group is transferred to the acyl accep-
tor amine through a second oxyanion intermediate and the 
amine becomes covalently linked to the  γ -glutamyl resi-
due via a peptide ( “ isopeptide ” ) bond, and the active-site 
cysteine becomes deacylated. If the primary amine is the 
 ε -amino group of a peptide/protein-bound lysine residue, 
the end-result is the cross-linking of two peptide chains. The 
measurement of released ammonia, (labeled) amine incor-
porated into a protein and the cross-linked product (see in 
red ellipses on Figure 1) all have been utilized for the mea-
surement of FXIII activity.  
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 The main physiological function of plasma FXIII is the 
cross-linking of fi brin  γ -chains into dimers and  α -chains into 
high molecular mass polymers. In addition it cross-links  α 2 -
plasmin inhibitor, the main physiological inhibitor of plas-
min, to fi brin  α -chain; fi rst a hetero-tetramer is formed, then, 
it becomes incorporated into  α -chain polymers. This way the 
action of FXIIIa makes the fi brin network resistant to shear 
stress and protects it from prompt elimination by the powerful 
fi brinolytic enzyme, plasmin  (2) . 
 There are two reasons why FXIII is determined in clini-
cal practice and clinical research: 1) the diagnosis of FXIII 
defi ciencies and monitoring FXIII substitution of defi cient 
patients; 2) elevated FXIII level might represent a risk factor 
of thrombotic diseases in certain conditions. The latter is a 
topic of clinical research rather then routine diagnostics  (5) . 
 Factor XIII defi ciencies 
 Inherited FXIII defi ciencies are classifi ed as FXIII-A and 
FXIII-B defi ciency. The former is a rare bleeding disorder, one 
diagnosed case in a population of two million. Its frequency 
might be ten times higher in populations in which consanguin-
eous marriage is a common practice. It can be classifi ed as 
type I defi ciency, a quantitative defect due to the decreased 
synthesis of the protein, and type II defi ciency, which is char-
acterized by normal or near normal concentration of FXIII-A 
with a functional defect. It is a very severe bleeding diathesis 
in the majority of patients not being on appropriate prophy-
lactic treatment. Umbilical stump bleeding appears in 80 % of 
FXIII-A defi cient newborns, later in life intramuscular, subcu-
taneous, and unfortunately, also intracranial hemorrhage occur 
in a high percentage of patients with serious, occasionally fatal, 
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 Figure 1  Schematic representation of the transglutaminase reaction catalyzed by activated FXIII (FXIIIa). 
 Different FXIII assays are based on the determination of the products encircled by red ellipses. 
outcome. For this reason, prophylactic FXIII supplementation 
is mandatory in severe FXIII-A defi ciency. FXIII-A defi ciency 
is frequently associated with impaired wound healing and 
leads to abortion in pregnant women. Repeated spontaneous 
abortions, even if the bleeding symptoms are only moderate, 
indicate investigations for FXIII-A defi ciency. Six families 
with inherited FXIII-B defi ciency have also been reported  (6) . 
In these cases the clinical symptoms were milder. 
 Acquired defi ciency due to a neutralizing or non-neutralizing 
autoantibody against either of the FXIII subunits also results 
in severe, often life-threatening bleeding symptoms. It may 
accompany an autoimmune disease, most frequently systemic 
lupus erythematosus, or may also occur in the absence of any 
disease in elderly patients. Less severe acquired FXIII defi -
ciencies may be due to consumption or decreased synthesis 
of FXIII subunits. In these cases the extent of decrease in 
plasma FXIII activity is moderate, rarely goes below 20 % . 
Most recent reviews provide detailed information on the clin-
ical symptoms in FXIII defi ciencies and on the classifi cation 
of the disease  (7 – 9) . 
 The offi cial communication of the International Society on 
Thrombosis and Haemostasis, Scientifi c, and Standardization 
Committee (ISTH, SSC) recommends the following algorithm 
for the diagnosis and classifi cation of FXIII defi ciencies  (7) : 
 A quantitative plasma FXIII activity assay is to be used (i) 
as  “ fi rst line ” screening test (see later). 
 If it is decreased, the subtype of FXIII defi ciency is es-(ii) 
tablished by the following tests.
 Measurement of complex FXIII (FXIII-A a) 2 B 2 ) antigen 
concentration in the plasma. If its concentration is de-
creased, FXIII-A and FXIII-B antigens should also be 
measured. 
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 Measurement of FXIII activity and FXIII-A antigen in b) 
platelet lysate. 
 If autoantibody against a FXIII subunit is suspected:(iii) 
 Mixing study, for the detection of neutralizing antibod-a) 
ies against FXIII-A (determination of FXIII activity in 
a mixture of normal plasma and the patient ’ s plasma). 
 The detection of non-neutralizing antibodies in binding b) 
assays (the binding of auto-antibodies to purifi ed FXIII-
A 2 or FXIII-B, usually in an ELISA type set-up). 
 Supplementary test for the evaluation of fi brin cross-(iv) 
linking [clot solubility test or sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE) analy-
sis of washed plasma clot]. 
 Exploration of the molecular genetic defect. (v) 
 The supporting information to this communication pro-
vides further practical details in this matter. 
 Table  1 indicates the generally reported FXIII values in dif-
ferent subclasses of FXIII defi ciencies as it was published in 
the offi cial ISTHSSC communication  (7) . 
 Due to methodological problems (see later) no evidence-
based data are available on the correlation between the 
severity of the disease and plasma FXIII activity. A further 
diffi culty is that FXIII defi ciency is one of the most unpre-
dictable conditions among coagulation factor defi ciencies; 
in non-substituted patients life-threatening spontaneous 
bleeding might follow long non-symptomatic intervals. 
The values given below are only for orientation; individual 
patients may behave differently. It is generally accepted that 
severe bleeding diathesis occurs at FXIII level below 3 % of 
FXIII activity. Patients with plasma FXIII activity between 
5 % and 30 % may bleed in hemostatic stress situations. The 
target pre-dose value in substituted patients is  > 5 % FXIII 
activity. This is  > 10 % during pregnancy and  > 30 % during 
labor. During major surgery FXIII activity  > 50 % is consid-
ered safe. 
 The effect of plasma FXIII level on the risk 
of thrombotic diseases 
 Earlier studies on association of the risk of coronary artery 
disease (CAD) and plasma FXIII levels included a relatively 
low number of male or predominantly male patients. The 
critical evaluation of these studies was recently published 
 (5) . The results of these studies were inconclusive, which 
was partly due to methodological problems (interference by 
FXIII-A Val34Leu polymorphism, see later) and partly to not 
differentiating between the risk of coronary sclerosis without 
myocardial infarction and the risk of the acute event, i.e., 
myocardial infarction developed in atherosclerotic coronary 
vessels. 
 In a relatively large study involving 955 patients (377 
females and 578 males) undergoing coronary angiography, 
participants were sub-grouped according to the presence 
or absence of signifi cant coronary sclerosis and accord-
ing to the presence or absence of the history of myocar-
dial infarction  (10) . In females, but not in males, adjusted 
FXIII levels were moderately, but signifi cantly elevated in 
patients with the history of myocardial infarction. FXIII 
levels in the upper tertile represented a 2.5 to  3.0-fold 
risk of myocardial infarction only in females. Elevated 
FXIII level did not increase the risk of developing signifi -
cant coronary sclerosis. Elevated FXIII level also exerted 
a similar gender-specifi c effect on the risk of peripheral 
artery disease  (11) . 
 A recent review  (12) enlists only two studies  (13, 14) on 
the association of FXIII level with the risk of venous throm-
boembolism. Elevated FXIII-A levels did not infl uence the 
risk of venous thromboembolism in a recent nested case-con-
trol study involving 462 participants who developed venous 
thromboembolism and 1047 participants who remained free 
of it  (14) . Further studies should explore if there is any gender 
or age specifi c difference. 
 Table 1  Diagnosis and classifi cation of FXIII defi ciencies. 
Defi ciency Plasma Platelet
FXIII activity FXIII-A 2 B 2 antigen FXIII-A antigen FXIII-B antigen FXIII activity FXIII-A antigen
Inherited
  FXIII-A defi ciency
  Type I (quantitative)  ↓ ↓ ↓  ↓ ↓ ↓  ↓ ↓ ↓  > 30 %  ↓ ↓ ↓  ↓ ↓ ↓ 
  Type II (qualitative)  ↓ ↓ ↓  ↓ -n  ↓ -n  > 30 %  ↓ ↓ ↓  ↓ -n
  FXIII-B defi ciency  ↓ ↓  ↓ ↓ ↓  ↓ ↓  ↓ ↓ ↓ n n
Autoantibody against FXIII
  Anti FXIII-A
  Neutralizing  ↓ ↓ ↓  ↓ -n  ↓ -n  > 30 % n n
  Non-neutralizing  ↓ ↓ ↓  ↓ ↓ ↓  ↓ ↓ ↓  > 30 % n n
  Anti-FXIII-B  ↓ ↓ ↓  ↓ ↓ ↓  ↓ ↓ ↓  ↓ ↓ ↓ n n
Other acquired defi ciencies a  ↓  ↓  ↓  ↓ -n na na
 ↓ ↓ ↓ , Highly decreased activity/concentration usually below 3 % , and in the majority of cases between non-detectable 1 % ;  ↓ ↓ , considerably de-
creased activity/concentration usually 5 % – 10 % ;  ↓ , slightly decreased activity usually in the range of 20 % – 70 % ; n, normal; na, non-applicable. 
The table indicates the generally reported abnormalities, exceptions may occur.  a Acquired FXIII defi ciencies due to increased consumption or 
decreased synthesis. The Table is reproduced from reference  (7) with permission. 
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 Functional FXIII assays 
 Clinical symptoms may indicate FXIII defi ciency, but the 
diagnosis is based on laboratory methods. The generally used 
screening tests for coagulopathies, prothrombin time, acti-
vated partial thromboplastin time and thrombin time are nor-
mal in FXIII defi ciency, unless there is another concomitant 
disorder in the clotting system. For instance, lupus antico-
agulant with prolonged activated partial thromboplastin time 
may occur in SLE patients with autoantibodies against FXIII. 
Full evaluation of the clotting system should include a special 
test for the detection of FXIII defi ciency. The functional  “ fi rst 
line ” screening assay is the key point in this respect. Due to 
traditional improper practice in screening, FXIII defi ciency is 
the most under-diagnosed bleeding diathesis. 
 In FXIII activity assays, FXIII is converted into an active 
transglutaminase by thrombin and Ca 2 +  and, in all, except one 
assay, the products of transglutaminase activity are measured. 
Figure 1 demonstrates the three possible products that can be 
determined (see red ellipses), and, accordingly, the methods 
for the measurement of FXIII activity are based on three dif-
ferent principles: 1) the detection of fi brin cross-linking activ-
ity of FXIIIa (clot solubility tests and SDS PAGE analysis of 
fi brin cross-linking), 2) the determination of small molecular 
weight amine substrates covalently cross-linked to a pro-
tein substrate by FXIIIa (amine incorporation assays), 3) the 
measurement of ammonia released in the fi rst step of trans-
glutaminase reaction (ammonia release assays). These assay 
principles and features of assays based on these principles are 
summarized in Table  2 . There is a single assay in which the 
isopeptidase activity of FXIIIa is measured. Qualitative/semi-
quantitative and quantitative functional FXIII assays will be 
discussed in detail. 
 Qualitative/semiquantitative FXIII assays based 
on fi brin cross-linking activity 
 Clot solubility assays  Traditionally, a plasma clot 
soluble in concentrated urea solution or in dilute acids was 
considered as the sign of FXIII defi ciency. The clot solubility 
test goes back to the discovery of FXIII when a plasma protein 
activity that renders the clot insoluble in the presence of Ca 2 +  
was demonstrated  (15 – 17) . In the test used for diagnostic 
purposes plasma samples are clotted by adding thrombin 
and/or Ca 2 +  and the clot is then suspended in 5 M or 8 M urea 
or in 2 % acetic acid or in 1% – 5 % monochloroacetic acid. 
The method is not standardized, in different applications of 
the tests the inducers of clotting (thrombin and/or CaCl 2 ) and 
their concentrations, the time allowed for clotting, the type 
and concentration of the solvents, the time of the detection 
of solubility, etc. are all variables which infl uence the limit 
of detection of FXIII activity. In different reports the limit 
of detection varied from  < 0.5 % to 5 % FXIII activity  (18 –
 21) , i.e., depending on the test conditions, moderate and 
sometimes even severe FXIII defi ciencies cannot by detected 
by these poorly standardized qualitative tests. For these 
reasons, using the clot solubility tests a considerable part of 
FXIII defi ciencies remain undiagnosed, therefore its use as  Ta
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the screening test for FXIII defi ciency was not recommended 
by the FXIII and Fibrinogen Subcommittee of ISTH, SSC 
 (7) . Most recently, based on experiments with mixtures of 
normal and FXIII defi cient plasma, it was claimed that if the 
clot formed from citrated plasma, i.e., in the absence of added 
Ca 2 +  , it remains soluble in 2 % acetic acid up-to 18.8 % FXIII 
activity. This fi nding has not been confi rmed with clinical 
samples  (22) . 
 In summary, it has be emphasized, that, although a positive 
clot solubility test is strongly indicative of FXIII defi ciency, 
the possibility of defi ciency is in no way excluded by a nega-
tive test. Another drawback of clot solubility assays are that 
they cannot be used for monitoring prophylactic treatment 
and substitution therapy and they are also useless in moderate 
acquired defi ciencies. 
 Several attempts have been made to design an at least semi-
quantitative clot solubility assay. Such attempts included the 
use of FXIII-depleted fi brinogen as  “ substrate ” with different 
plasma dilutions  (23, 24) or the modifi cation of clot solubil-
ity assay by adding increasing amounts of FXIIIa inhibitors, 
such as iodoacetate  (25) or antiserum specifi c to FXIII-A sub-
unit  (26) , to the undiluted plasma sample and determine the 
amount of inhibitor necessary to neutralize FXIIIa cross-link-
ing activity. In a further modifi cation of the clot lysis assay 
 (27) fi brinogen coated latex beads were exposed to thrombin. 
The beads aggregated as the consequence of interbead fi brin 
polymerization and in the absence of FXIII, the aggregates 
rapidly dissociated in 5 M urea. FXIII dose dependently 
inhibited the dissociation, which was quantifi ed by turbidi-
metry. These, in most cases poorly evaluated and standard-
ized assays, did not gain popularity, partly because they are 
more cumbersome, time consuming and, in some cases, more 
expensive than commercially available rapid assays. 
 Fibrin clot analysis by SDS PAGE  Fibrin cross-linking in 
plasma clot can be evaluated by SDS PAGE  (28) . In this case 
plasma is clotted by thrombin and Ca 2 +  , then the recovered 
fi brin clot is extensively washed to remove trapped, non-
covalently attached proteins. The washed clot is dissolved 
in sample buffer and analyzed by SDS PAGE for  γ -chain 
dimerization and  α -chain cross-linking. As fi brin  γ -chain 
dimerization is a highly sensitive function of FXIIIa, even 
traces (below 1 % ) of FXIII activity can be demonstrated by 
this qualitative or semi-quantitative test. Impaired fi brin cross-
linking caused by fi brinogen abnormality can also detected by 
this test. The procedure is cumbersome and time-consuming 
and it is only used as a supplementary test in the diagnosis of 
FXIII defi ciency. 
 Quantitative FXIII assays 
 In all quantitative assays, FXIII is fi rst (or during the lag phase 
of the reaction) activated by thrombin and Ca 2 +  . However, the 
transformation of fi brinogen into fi brin by thrombin causes 
diffi culties in the separation of free amines from protein-
bound amines and fi brin would also interfere with photomet-
ric or fl uorimetric assays. The elimination of this problem 
has been solved in the following ways: 1) Traditionally, the 
denaturation of fi brinogen in plasma samples and detachment 
of FXIII from fi brinogen prior to the assays was achieved by 
a short heat treatment at 56 ° C in the presence of glycerol or 
ethyleneglycol  (29) . It was expected that such a mild heat 
treatment separates FXIII from fi brinogen and leaves it intact. 
However, this was not quite the case and it was shown that a 
signifi cant unpredictable quantity of FXIII activity was lost 
during heat treatment  (30) . A higher recovery of FXIII was 
achieved when fi brinogen was removed from the plasma by 
adsorption to bentonite  (30, 31) . Bentonite treatment needed 
an extra step of centrifugation and now the elimination of 
fi brinogen by heat treatment and adsorption are only of histor-
ical interest; 2) The prevention of fi brin polymerization in the 
FXIII assay mixture by a polymerization inhibitory peptide 
was fi rst introduced by Miraglia and Greenberg  (32) and later 
it became popular to include peptides, like GPRP or GPRPA, 
in the FXIII assay mixture  (33 – 35) ; 3) Finally, in highly sen-
sitive amine incorporation assays the high dilution of plasma 
samples prevent the formation of fi brin polymers  (36 – 38) . It 
is to be noted that by eliminating fi brinogen and preventing 
fi brin polymerization, the FXIII activation accelerating effect 
of polymerized fi brin is lost and rather high thrombin concen-
tration is needed to bring about full activation of FXIII. 
 Another general problem of FXIII activation concerns one 
of the polymorphisms of FXIII-A. A Val to Leu amino acid 
replacement just three amino acids up-stream of the thrombin 
cleavage site in the activation peptide, turned out to affect sig-
nifi cantly the rate of FXIII activation by thrombin. The initial 
activation of the Leu34 variant proceeds 2.5-fold faster, while 
the activity of fully activated FXIIIa is identical in all geno-
types  (39 – 41) . Only two studies investigated the infl uence of 
FXIII Val34Leu polymorphisms on the measurement of FXIII 
activity. The assay described by Wilmer et al. measures trans-
glutaminase activity at the initial stage of FXIII activation 
 (36) , and the results obtained by this assay refl ect the rate of 
FXIII activation rather than the catalytic concentration. FXIII 
activity values obtained with the Leu34 variant are signifi -
cantly higher than those obtained with same concentration of 
the Val34 variant  (36, 42) . For this reason different expected 
values were reported for wild type (39.3 % – 100.4 % ), for 
heterozygote (34.5% – 183.0 % ) and for homozygote (96.3% –
 226.0 % ) individuals. The assay shows poor correlation with 
the antigenic assay and with activity assays not infl uenced by 
the polymorphism. Users should be aware of this problem. In 
contrast, the assay described by K á rp á ti et al.  (34) and very 
likely also the assay reported by Fickenscher et al.  (33) , mea-
sure the transglutaminase activity of fully activated enzyme 
and the results are not infl uenced by FXIII-A Val34Leu geno-
type. Unfortunately, other assays have not been tested for the 
effect of FXIII-A Val34Leu polymorphism. 
 A signifi cant step in the standardization of FXIII assays was 
the establishment of a WHO reference plasma by the FXIII 
Working Party of ISTH, SSC  (43) . This plasma with assigned 
FXIII activity and plasma FXIII antigen values is available 
from the National Institute for Biological Standards and 
Control (Potters bar, UK) and it is to be used for the calibra-
tion of reference plasmas by companies producing FXIII assay 
kits. 
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 Amine incorporation assays  The fi rst quantitative FXIII 
assays were based on the principle of amine incorporation. 
Table  3 enumerates the publications on such assays that 
were used for the determination of FXIII activity in 
human plasma. In these assays the covalent binding of an 
acyl acceptor substrate amine to an acyl donor glutamine 
residue of a protein by FXIIIa is measured. As discussed 
above the elimination of interfering fi brin formation was 
fi st solved by previous heat treatment of fi brinogen  (29, 
44, 46 – 49) or by fi brinogen adsorption to bentonite  (31) . 
More recently only fi brin polymerization inhibitory peptide 
 (32, 35) and prevention of fi brin polymerization by high 
plasma dilution  (35 – 38) are used for this purpose. One of 
the burdens of amine incorporation assays is the separation 
of free non-bound amines from protein linked ones. This was 
fi rst solved by acid precipitation and removal of unbound 
amines by repeated washing of the protein precipitate  (29, 
32, 44, 45, 47, 48) . Later the separation was simplifi ed by 
the use of substrate proteins covalently or non-covalently 
bound to a surface  (31, 35 – 38, 46) . The disadvantage of this 
simplifi cation was that the substrate protein could not be used 
at saturating concentration, which impaired the precision of 
the assay. 
 Casein  (29, 38, 44 – 47, 49) , casein derivatives  (31, 32, 48) 
and fi brinogen  (35 – 37) are the Gln donor substrate proteins 
used in various amine incorporation assays. Hammerstein 
casein is a mixture of different casein molecules. In addi-
tion to substrate Gln residues they also contain Lys residues, 
which are substrates for FXIIIa and these Lys residues com-
pete with the amine substrates in the assay. Blocking the Lys 
residues by methylation or acetylation overcame this problem 
 (31, 32, 48, 50) . Besides, there are a number of Gln residues 
in casein to which FXIIIa cross-links amines with different 
kinetics. A further problem was the gradual precipitation 
of substrate casein in the presence of Ca ions. Acetylated, 
dephosphorylated  β -casein is exempt of these problems  (50) , 
however it is not available commercially and its produc-
tion is rather laborious. Fibrinogen, as opposed to fi brin, is 
a rather poor substrate of FXIIIa. However, the adsorption to 
a surface signifi cantly improves the substrate characteristics 
of fi brinogen. 
 Fluorescent dansylcadaverine  (29, 49) , radiolabeled putres-
cine  (32, 44 – 47) , or biotinylated cadaverine (biotinamido-
pentylamine)  (31, 35 – 37) are the most frequently used amine 
substrates in FXIII assays. Putrescine is a diamine and it can 
provide two primary amine groups for the transglutaminase 
reaction, i.e., protein-linked putrescine still can offer its 
remaining free amine for cross-linking two protein mole-
cules. This again, might infl uence the kinetics of the transglu-
taminase reaction. Although this is not a problem with other 
radiolabeled amine substrates, like glycine ethylesther or 
histamine, these amines have not been used in plasma FXIII 
assays. 
 Some of the assays use very long incubation times, up-to 4 h 
(Table 3). Activated FXIII is a rather instable enzyme and 
after 30 min gradually looses its activity at 37 ° C (unpub-
lished observation). For this reason incubation longer than 30 
min is not recommended. The measurement of incorporated 
fl uorescent or radiolabeled amines is straightforward. This 
is not the case with biotinylated cadaverine; in this case a 
separate detection reaction using streptavidin conjugated 
with a fl uorophore  (35) or with an enzyme  (31, 36, 37) is 
required. The detection using enzymatic (alkaline phosphates 
or  β -galactosidase) reaction prolongs the assay time and it 
should be carefully controlled. 
 In general, the advantage of amine incorporation methods is 
their high sensitivity due to the use of fl uorescent, radiolabeled 
amines or the detection of the incorporated biotin moieties by an 
enzymatic reaction. The methods using dansyl-cadaverine can 
detect as low as 1 % plasma FXIII activity, while the sensitivity 
of the other methods goes even below that limit. However, the 
amine incorporation methods are rather troublesome and time-
consuming, to perform an assay takes long hours. They are 
diffi cult to standardize and the separation step makes it hardly 
possible to design a true kinetic assay. A pseudo-kinetic assay 
can be designed when the incorporation is determined at vari-
ous times after the initiation of the reaction. 
 Ammonia release assays  The fi rst FXIII assay utilizing 
the measurement of ammonia released by FXIIIa from its Gln 
donor protein substrate was published in 1969  (51) . In this case 
ammonia formed in recalcifi ed clotted plasma was estimated. 
Further early methods determined ammonia formed in 
plasma or plasma supplemented with fi brinogen by ammonia 
selective electrode  (52) or a modifi ed Berthelot reaction  (53) . 
These end-point methods were impractical and required a 
high volume of plasma, they did not gain popularity. 
 A new principle was introduced by using glutamate dehydro-
genase (GlDH) indicator reaction for monitoring the produc-
tion of ammonia  (30) . This principle made it possible to design 
the fi rst true kinetic FXIII assay  (30) . In the assay, fi brinogen 
was removed by bentonite treatment. FXIII was activated by 
thrombin and Ca 2 +  during the lag phase of the reaction. FXIIIa 
cross-linked the amine substrate (ethylamine) to the single sub-
strate Gln residue in acetylated dephosphorylated  β -casein and 
ammonia was released. The ammonia release was continuously 
monitored by glutamate dehydrogenase-mediated indicator 
reaction, in which NADPH became converted into NADP and 
the decrease in absorbance at 340 nm was measured. 
 The above principle was used in the development of two 
kinetic ammonia release FXIII assays (Figure 2)  (33, 34) . In the 
new modifi ed assays fi brin formation was prevented by peptides 
that inhibited fi brin polymerization, the protein substrate was 
replaced by Gln containing oligopeptides and glycine ethyles-
ther was used as amine substrate (Table  4 ). Both modifi ed assays 
are now commercially available as Berichrom FXIII (Siemens, 
Marburg, Germany), REA-chrom FXIII (Reanal-ker, Budapest, 
Hungary) and TECHNOCHROM FXIII (Technoclone, Vienna, 
Austria) tests. These ammonia release assays are quick (only 
10 min), one-step, true kinetic tests with good reproducibility 
and can be easily automated. Neither assay is infl uenced by the 
FXIII-A Val34Leu polymorphism  (33, 34, 54) . They are widely 
used as screening tests for FXIII defi ciency. The Berichrom 
and TECHNOCHROM assays are compared in Table 4 (the 
Rea-chrom assay is identical with the TECHNOCHROM 
assay). The two kits use different Gln containing substrate 
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oligopeptides; in the Berichrom assay the decapeptide possesses 
an amino acid sequence similar to that of  β -casein around the 
substrate Gln residue, the sequence of the dodecapeptide used 
in the TECHNOCHROM (and Rea-chrom) kit is identical with 
the N-terminal sequence of N1-isoform of  α 2 -plasmin inhibitor. 
In the indicator reaction NADH and NADPH are used in the 
Berichrom and TECHNOCHROM assays, respectively. 
 One of the problems to be discussed concerning the 
ammonia release FXIII assays comes from the ammonia pro-
ducing and NADH consuming reactions in the plasma that 
result in decreased absorbance at 340 nm independently of 
FXIIIa activity. Lactate dehydrogenase present in the plasma 
is a major source of the NADH consuming side-reaction. 
The LDH substrate, pyruvate, is also present in the plasma, 
and its transformation to lactate directly consumes NADH, 
but not NADPH  (55) . FXIIIa-independent ammonia produc-
tion in the plasma samples is another source of non-specifi c 
NAD(P)H consumption  (56, 57) . An example for such a 
reaction is the production of ammonia by the de-amidation 
of glutamine by  γ -glutamyl transferase present in the plasma. 
The extent of these side-reactions varies individually and, 
if not subtracted, results in overestimation of FXIII activity 
 (58) . Such an overestimation adds 2 % – 15 % to plasma FXIII 
activity, which does not seem to cause clinically signifi cant 
problem around the normal range, however in FXIII defi -
cient patients gives false information on the severity of FXIII 
defi ciency and on the effi ciency of replacement therapy  (9, 
34, 54, 58) . The overestimation of FXIII activity in the low 
activity range by the Berichrom FXIII assay was also demon-
strated by surveys of the ECAT external quality assessment 
program  (59) . To avoid the overestimation of FXIII activity 
the subtraction of a plasma blank, in which FXIIIa is inhibi-
ted by 1 mM iodoacetamide, is recommended  (34, 54, 58) . 
A reagent for plasma blank measurement is included in the 
REA-chrom and TECHNOCHROM kits; in the Berichrom 
assay, plasma blank reagent is to be prepared by the user. 
 The disadvantage of the above assays is their relatively 
low sensitivity. In our hands, their limit of quantitation var-
ied 3 % – 10 % depending on the instruments used for FXIII 
activity determination. Unfortunately, this range is important 
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2.  Transglutaminase reaction:
Gly-OEt + Q-peptide Q-peptide-Gly-OEt +NH3
FXIIIa
1. Activation during
the lag phase:
FXIII FXIIIa
Ca2+
thrombin
Inhibition of fibrin polymerization by GPRP(A)
NH3 + -ketoglutarate+NAD(P)H glutamate + NAD(P) 
GlDH
3.  Monitoring the release of ammonia:
 Figure 2  Kinetic photometric ( “ chromogenic ” ) factor XIII assays 
based on monitoring ammonia released during the transglutaminase 
reaction. 
 Gly-OEt, glycine ethylesther; Q-peptide, glutamine containing acyl 
donor substrate peptide; GlDH, glutamate dehydrogenase. 
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 Table 4  Composition of commercial ammonia release (chromogenic) FXIII activity assays. 
Assay kit Berichrom FXIII 
Siemens, Marburg, Germany
TECHNOCHROM FXIII 
Technoclone, Vienna, Austria
Fibrin polymerization inhibitory peptide G-P-R-P-A G-P-R-P
FXIII activator Thrombin + Ca 2 +  Thrombin + Ca 2 +  
Acyl donor Q-peptide L-G-P-G-Q-S-K-V-I-G N-Q-E-Q-V-S-P-L-T-L-L-L-K
Acyl acceptor amine Glycine ethylesther Glycine ethylesther
Indicator reaction GlDH with NADH GlDH with NADPH
Plasma blank reagent in the kit Not included Included
Plasma:reagent volume ratio 1:10 1:10
 The amino acid sequence of the peptide in the Berichrom kit corresponds, with some modifi cation, to the sequence of  β -casein around the 
substrate Gln residue. The sequence of the dodecapeptide in the TECHNOCHROM kit corresponds to the N-terminal sequence of the FXIIIa 
substrate  α 2 -plasmin inhibitor isoform (N1  α 2 -plasmin inhibitor)  (42) . GlDH, glutamate dehydrogenase. 
for the stratifi cation of disease severity and for controlling 
the replacement therapy. With a slight modifi cation of the 
TECHNOCHROM assay, doubling the sample volume and 
extending the measuring interval after the 5 min lag period 
from 5 to 10 min, we were able to measure FXIII activity below 
5 % with good linearity and acceptable repeatability (Figure  3 ). 
The modifi ed assay satisfi es most of the requirements of clini-
cal diagnostics and monitoring replacement therapy. If an even 
more sensitive assay is needed, e.g., for studies of phenotype-
genotype correlation in the very low activity range, one of the 
amine incorporation assays is recommended. 
 Kappel et al. modifi ed the Berichrom FXIII assay  (60) 
by replacing NADH for thio-NADH in the indicator reac-
tion, this way the measuring wavelength was brought into 
the visible range (405 nm) commonly available on coagu-
lometers with optical channel. The change of the cofactor 
however does not eliminate the problem caused by NADH 
consuming and ammonia producing side reactions (see 
above) and the modifi cation did not improve the sensitivity 
of the assay  (59) . 
 FXIII assay based on the determination of isopeptidase 
activity  An interesting concept for the determination of 
FXIII activity was put forward by Parameswaran et al.  (61) . 
It was shown that in certain conditions FXIIIa can exert 
isopeptidase activity, i.e., as opposed to its cross-linking 
activity, it can release primary amines bound to a Gln residue 
in an oligopeptide. They used a primary amine labeled with a 
quencher, and a peptide substrate that contained a fl uorophore. 
Gradual removal of the quencher containing amine by FXIIIa 
resulted in increasing fl uorescence. This assay was modifi ed 
and made more sensitive by Oertel et al.  (62) . They used 
2-aminobenzoyl fl uorophore labeling at the N-terminus of the 
peptide corresponding to the N-terminal amino acid sequence 
of  α 2 -plasmin inhibitor and dinitrophenyl cadaverine as internal 
quencher. Fluorescence was measured at 418 nm (excitation 
at 313 nm). The reagent is commercially available for 
research use from Zedira (Darmstadt, Germany). The limit of 
quantitation (5 % FXIII activity) of the fl uorimetric assay does 
not compare favorably to that of the widely used photometric 
ammonia release assays. Its correlation with the FXIII-A 
subunit ELISA was poorer than that of the photometric assay 
and the correlation with the photometric transglutaminase 
assay was not very good, either  (62) . It remains to be seen 
to what extent the measured isopeptidase activity refl ects the 
physiologically important cross-linking activity of FXIIIa. 
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